{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:56:38Z","timestamp":1759010198427},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T00:00:00Z","timestamp":1110499200000},"content-version":"vor","delay-in-days":100,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Zygomycosis is associated with a high mortality in immunosuppressed patients. Treatment typically includes surgical resection and administration of intravenous amphotericin B. Success of treatment may require withdrawal of immunosuppression, with risk of graft loss. We report the successful treatment of invasive pulmonary zygomycosis, following initial surgical resection, using very high doses of lipid\u2010based amphotericin B without withdrawal of immunosuppression. The patient received daily doses up to 10\u2003mg\/kg\/day (51\u2003g cumulatively) of lipid\u2010based amphotericin B along with a brief course of intrapleural amphotericin. Despite immunosuppression not being withdrawn, the patient's kidney allograft function remained stable. We conclude that high doses of lipid\u2010based amphotericin B can be safe and effective as part of the treatment regimen for pulmonary zygomycosis.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2004.00076.x","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T11:45:51Z","timestamp":1110541551000},"page":"183-187","source":"Crossref","is-referenced-by-count":8,"title":["Lipid\u2010based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient"],"prefix":"10.1111","volume":"6","author":[{"given":"J.A.","family":"Crompton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.S.","family":"Shihab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00037-5"},{"key":"e_1_2_5_3_2","first-page":"331","article-title":"Mucormycosis in patients with haematological malignancies","volume":"99","author":"Pagano L","year":"1997","journal-title":"a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)"},{"key":"e_1_2_5_4_2","first-page":"1301","article-title":"Pulmonary mucormycosis","volume":"159","author":"Lee FY","year":"1999","journal-title":"the last 30 years"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2473063.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-2-200207160-00008"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.267"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.834-840.2002"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.828-833.2002"},{"issue":"1","key":"e_1_2_5_11_2","first-page":"21","article-title":"AmBisome","volume":"49","author":"Adler\u2010Moore J","year":"2002","journal-title":"liposomal formulation, structure, mechanism of action and pre-clinical experience"},{"key":"e_1_2_5_12_2","first-page":"1044","article-title":"Pulmonary mucormycosis","volume":"57","author":"Tedder M","year":"1994","journal-title":"results of medical and surgical therapy"},{"key":"e_1_2_5_13_2","first-page":"1463","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Krensky AM","year":"2001"},{"key":"e_1_2_5_14_2","first-page":"12","article-title":"Immunosuppressive effects of beta\u2010herpesviruses","volume":"10","author":"Boeckh M","year":"2003","journal-title":"Herpes"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200201243460403"},{"key":"e_1_2_5_16_2","first-page":"579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours","volume":"322","author":"Eriksson U","year":"2001","journal-title":"randomised controlled trial"},{"key":"e_1_2_5_17_2","first-page":"316","article-title":"Nephrotoxicity of cyclosporine A and amphotericin B\u2010deoxycholate as continuous infusion in allogenic stem cell transplantation","volume":"132","author":"Furrer K","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_5_18_2","first-page":"455","article-title":"Tolerability, safety and efficacy of conventional amphotericin B administered by 24\u2010hour infusion to lung transplant recipients","volume":"132","author":"Speich R","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_5_19_2","first-page":"943","article-title":"Continuous infusion of escalated doses of amphotericin B deoxycholate","volume":"36","author":"Imhof A","year":"2003","journal-title":"an open-label observational study"},{"key":"e_1_2_5_20_2","first-page":"803","article-title":"Continuous and 4 h infusion of amphotericin B","volume":"54","author":"Peleg AY","year":"2004","journal-title":"a comparative study involving high-risk haematology patients"},{"key":"e_1_2_5_21_2","first-page":"871","article-title":"The solubility ceiling","volume":"37","author":"Lewis RE","year":"2003","journal-title":"a rationale for continuous infusion amphotericin B therapy?"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg020"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1581-1582.2002"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.2950-2956.1998"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2004.00076.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2004.00076.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:16:58Z","timestamp":1696871818000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2004.00076.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1399-3062.2004.00076.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2004.00076.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}